Andrea Rocca, Daniele Andreis, Anna Fedeli, Roberta Maltoni, Samanta Sarti, Lorenzo Cecconetto, Elisabetta Pietri, Alessio Schirone, Sara Bravaccini, Patrizia Serra, Alberto Farolfi, Dino Amadori
INTRODUCTION: Pertuzumab is a recombinant, humanized monoclonal antibody that binds to the dimerization domain of human epidermal growth factor receptor 2 (HER2), inhibiting the heterodimerization of HER2 with other HER receptors. It has shown synergy with trastuzumab in preclinical studies, and has led to a significant prolongation of progression-free and overall survival compared with placebo when added to trastuzumab and docetaxel for the first-line treatment of HER2-positive metastatic breast cancer (BC)...
2015: Expert Opinion on Drug Metabolism & Toxicology